Tuesday, September 23rd14.1°C
23284
22455

Mylan to buy Abbott's branded generic-drug businesses outside US for $5.3B in stock

PITTSBURGH, Pa. - The generic drugmaker Mylan is buying Abbott Laboratories' generic-drugs business in developed markets for stock valued at about $5.3 billion.

Mylan said Monday that the deal will diversify and expand its business outside the U.S. The combined company will be organized in the Netherlands, which will help reduce its tax expenses. The company will keep its headquarters near Pittsburgh.

The deal is expected to lower Mylan's tax rate to approximately 20 per cent to 21 per cent in the first full year, and to the high teens after that.

Several other U.S. companies are using mergers to reincorporate in countries with lower tax rates. These moves are raising concerns among U.S. lawmakers because they can cost the federal government billions in tax revenue.

The business to be acquired by Mylan encompasses more than 100 generic and specialty drugs sold in Europe, Japan, Canada, Australia and New Zealand. Some of the products include Creon, Influvac, Brufen, Amitiza and Androgel. It also include manufacturing plants in France and Japan.

The portfolio of products accounted for about $2 billion in sales last year.

Abbott is keeping its branded generic drug business in emerging markets. That business had 2013 sales of $2.9 billion. It is also keeping its other businesses and products in developed markets.

Abbott will own about 21 per cent of the combined Mylan company — which will be called Mylan NV — but does not intend to remain a long-term shareholder. Shares of Mylan NV will trade on the Nasdaq under Mylan's existing ticker symbol, "MYL."

The transaction is expected to about double Mylan's revenue in Europe by strengthening its presence in countries such as Italy, the U.K., Germany, France, Spain and Portugal. It also is expected to more than double Mylan's revenue in Canada and Japan, and strengthen its business in Australia and New Zealand. The deal also gives Mylan a meaningful presence in the specialty and branded generics market in Central and Eastern Europe.

The deal is expected to close in early 2015. It is expected to immediately add to Mylan's earnings, to the tune of about 25 cents per share in adjusted earnings in the first year, increasing through 2018.

Mylan Inc. is based in Canonsburg, Pennsylvania.

Mylan's stock added $2.10, or 4.2 per cent, to $52.30 in premarket trading, while shares of Abbott gained 94 cents, or 2.3 per cent, to $42.24 .

The Canadian Press


Read more Business News

23392


Recent Trending




Today's Market
S&P TSX15129.00-136.35
S&P CDNX928.09-26.97
DJIA17172.68-107.06
Nasdaq4527.689-52.10
S&P 5001994.29-16.11
CDN Dollar0.9068+0.0011
Gold1218.90+1.00
Oil91.50-0.91
Lumber332.20+5.60
Natural Gas3.909+0.001

 
Okanagan Companies
Pacific Safety0.17+0.01
Knighthawk0.01-0.005
QHR Technologies Inc1.27-0.10
Cantex0.04-0.01
Anavex Life Sciences0.2195-0.0035
Metalex Ventures0.05-0.01
Russel Metals35.37-0.38
Copper Mountain Mining2.40-0.26
Colorado Resources0.16-0.005
ReliaBrand Inc0.0206-0.0043
Sunrise Resources Ltd0.02-0.005
Mission Ready Services0.27-0.02

 



21337

FEATURED Property
19739998-950 Lanfranco Road
2 bedrooms 2 baths
$399,000
more details
image2image2image2
Click here to feature your property
Please wait... loading


Is this a fair offer from ICBC?

“Is this a fair offer from ICBC?”…. “How much should I settle for?”… “What is my claim worth?” These are just some of the questions I regularly get as...


Disruptive innovation

Last night I was privileged to be able to speak at the Greater Westside Board of Trade business awards dinner. Photo: ContributedI talked about Innovation and Collaboration which are two very interes...


Executors and their duties

There will be a time when you will need to decide who you should appoint as executor of your Will. As well, there may be a time when you will be asked by someone to act as the executor of his or her W...

_



23499




Member of BC Press Council


22620